Login Register Cart 0
Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1389-5575
ISSN (Online): 1875-5607

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Recent Approaches of Repositioning and Traditional Drugs for the Treatment of COVID-19 Pandemic Outbreak

Author(s): Nitin Tandon, Vijay Luxami, Runjhun Tandon* and Kamaldeep Paul*

Volume 21, Issue 8, 2021

Published on: 24 November, 2020

Page: [952 - 968] Pages: 17

DOI: 10.2174/1389557520666201124141103

Price: $65

Abstract

The recent emergence of novel, pathogenic COVID-19 disease associated with SARSCoV- 2 virus in China and its rapid national and international spread pose a global health emergency. The development of a new drug is tedious and may take decades to develop and involve multiple steps like the development of prototypes and phase I to III human trials, which involve the study on small to large populations to examine the safety and side effects associated with the drug under trials. Due to continous increase in the number of confirmed cases and deaths, there is an urgent need to develop a drug that is effective to kill the SARS-CoV-2 virus with fewer side effects to the human body. Therefore, this review focus on the latest advances in the development for the treatment of COVID-19 disease associated with SARS-CoV-2 with repositioning of already marketed drug with small molecules, as well as Chinese traditional medicines with established safety and efficacy which are being used for different therapeutic uses.

Keywords: SARS-CoV-2, chloroquine, hydroxychloroquine, chinese traditional medicine, inhibitors, stem cells.

« Previous Next »
Graphical Abstract

[1]
Anthony, S.J.; Johnson, C.K.; Greig, D.J.; Kramer, S.; Che, X.; Wells, H.; Hicks, A.L.; Joly, D.O.; Wolfe, N.D.; Daszak, P.; Karesh, W.; Lipkin, W.I.; Morse, S.S.; Mazet, J.A.K.; Goldstein, T. Global patterns in coronavirus diversity., 2017.
[2]
Báez-Santos, Y.M.; St John, S.E.; Mesecar, A.D. The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds. Antiviral Res., 2015, 115, 21-38.
[http://dx.doi.org/10.1016/j.antiviral.2014.12.015] [PMID: 25554382]
[3]
Chan, J.F.; Kok, K.H.; Zhu, Z.; Chu, H.; To, K.K.; Yuan, S.; Yuen, K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect., 2020, 9(1), 221-236.
[http://dx.doi.org/10.1080/22221751.2020.1719902] [PMID: 31987001]
[4]
Chang, X.J.; Xiao, W.; Zhang, S.; Chang, Y.P.; Chen, C.M.; Chen, J. Mechanism of Re Du Ning injection on anti-acute lung injury in rats based on cytokines storm. Chin. Herb. Med., 2014, 46, 236-239.
[5]
Chen, H.; Du, Q. 2020.
[6]
Chen, X.; Gan, Y.; Li, W.; Su, J.; Zhang, Y.; Huang, Y.; Roberts, A.I.; Han, Y.; Li, J.; Wang, Y.; Shi, Y. The interaction between mesenchymal stem cells and steroids during inflammation. Cell Death Dis., 2014, 5e1009
[http://dx.doi.org/10.1038/cddis.2013.537] [PMID: 24457953]
[7]
Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.; Shen, C.; Li, X.; Peng, L.; Huang, D.; Zhang, J.; Zhang, S.; Wang, F.; Liu, J.; Chen, L.; Chen, S.; Wang, Z.; Zhang, Z.; Cao, R.; Zhong, W.; Liu, Y.; Liu, L. Experimental treatment with favipiravir for COVID-19: An open-label control study. Engineering (Beijing), in press
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
[8]
Colson, P.; Rolain, J-M.; Lagier, J-C.; Brouqui, P.; Raoult, D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int. J. Antimicrob. Agents, 2020, 55(4)105932
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105932] [PMID: 32145363]
[9]
Deng, L.; Zeng, Q.; Liu, X.; Li, X.; Zhang, H.; Hong, Z.; Xia, J. Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: A retrospective cohort study. J. Infect. Dis., 2020.
[10]
Du, L.; He, Y.; Zhou, Y.; Liu, S.; Zheng, B-J.; Jiang, S. The spike protein of SARS-CoV––a target for vaccine and therapeutic development. Nat. Rev. Microbiol., 2009, 7(3), 226-236.
[http://dx.doi.org/10.1038/nrmicro2090] [PMID: 19198616]
[11]
Elfiky, A.A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci., 2020, 248, 117477-117482.
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[12]
Feldman, B.J. Glucocorticoids influence on mesenchymal stem cells and implications for metabolic disease. Pediatr. Res., 2009, 65(2), 249-251.
[http://dx.doi.org/10.1203/PDR.0b013e3181909c08] [PMID: 19262295]
[13]
Gautrat, P.; Laqier, J.C.; Parola, P.; Hoanq, V.T.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V.E.; Dupont, H.T.; Honoro, S.; Colson, P.; Chabriere, E.; La Scola, B.; Rolain, J.M.; Brouqui, P.; Raoult, D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents, in press
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105949]
[14]
Ziebuhr, J.; Snijder, E.J.; Gorbalenya, A.E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol., 2000, 81(Pt 4), 853-879.
[http://dx.doi.org/10.1099/0022-1317-81-4-853] [PMID: 10725411]
[15]
Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N-H.; Nitsche, A.; Müller, M.A.; Drosten, C.; Pöhlmann, S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, 2020, 181(2), 271-280.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[16]
Holshue, M.L.; DeBolt, C.; Lindquist, S.; Lofy, K.H.; Wiesman, J.; Bruce, H.; Spitters, C.; Ericson, K.; Wilkerson, S.; Tural, A.; Diaz, G.; Cohn, A.; Fox, L.; Patel, A.; Gerber, S.I.; Kim, L.; Tong, S.; Lu, X.; Lindstrom, S.; Pallansch, M.A.; Weldon, W.C.; Biggs, H.M.; Uyeki, T.M.; Pillai, S.K. Washington State 2019-nCoV case investigation team. First case of 2019 novel coronavirus in the United States. N. Engl. J. Med., 2020, 382(10), 929-936.
[http://dx.doi.org/10.1056/NEJMoa2001191] [PMID: 32004427]
[17]
Kim, M.J.; Ryu, C.H.; Kim, S.M.; Lim, J.Y.; Kim, W.S.; Jeun, S-S. Combined treatment with methylprednisolone and human bone marrow-derived mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis. Tissue Eng. Regen. Med., 2018, 15(2), 183-194.
[http://dx.doi.org/10.1007/s13770-017-0101-y] [PMID: 30603546]
[18]
Kobayashi, S.; Kimura, F.; Kobayashi, A.; Sato, K.; Motoyoshi, K. Influenza virus reactivation after remission with oseltamivir treatment in a patient undergoing nonmyeloablative bone marrow transplantation. J. Infect. Chemother., 2008, 14(4), 308-310.
[http://dx.doi.org/10.1007/s10156-008-0615-2] [PMID: 18709535]
[19]
Leng, Z.; Zhu, R.; Hou, W.; Feng, Y.; Yang, Y.; Han, Q.; Shan, G.; Meng, F.; Du, D.; Wang, S.; Fan, J.; Wang, W.; Deng, L.; Shi, H.; Li, H.; Hu, Z.; Zhang, F.; Gao, J.; Liu, H.; Li, X.; Zhao, Y.; Yin, K.; He, X.; Gao, Z.; Wang, Y.; Yang, B.; Jin, R.; Stambler, I.; Lim, L.W.; Su, H.; Moskalev, A.; Cano, A.; Chakrabarti, S.; Min, K.J.; Ellison-Hughes, G.; Caruso, C.; Jin, K.; Zhao, R.C. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis., 2020, 11(2), 216-228.
[http://dx.doi.org/10.14336/AD.2020.0228] [PMID: 32257537]
[20]
Linag, B.; Chen, J.; Li, T.; Wu, H.; Yang, W.; Li, Y.; Li, J.; Yu, C.; Nie, F.; Ma, Z.; Yang, M; Nie, P.; Gao, Y.; Quian, C.; Hu, M. 2020.
[21]
Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; Albaiu, D. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent. Sci., 2020, 6(3), 315-331.
[http://dx.doi.org/10.1021/acscentsci.0c00272] [PMID: 32226821]
[22]
Liu, F.; Xu, A.; Zhang, Y.; Xuan, W.; Yan, T.; Pan, K. Yu W., Zhang J. (2020). Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int. J. Infect. Dis., in press
[23]
Memish, Z.A.; Perlman, S.; Van Kerkhove, M.D.; Zumla, A. Middle East respiratory syndrome. Lancet, 2020, 395(10229), 1063-1077.
[http://dx.doi.org/10.1016/S0140-6736(19)33221-0] [PMID: 32145185]
[24]
Sahraei, Z.; Shabani, M.; Shokouhi, S.; Saffaei, A. Aminoquinolines against coronavirus disease 2019 (COVID-19): Chloroquine or hydroxychloroquine. Int. J. Antimicrob. Agents, 2020, 55(4)105945
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105945] [PMID: 32194152]
[25]
Sridhar, S. Clinical development of Ebola vaccines. Ther. Adv. Vaccines, 2015, 3(5-6), 125-138.
[http://dx.doi.org/10.1177/2051013615611017] [PMID: 26668751]
[26]
Stebbing, J.; Phelan, A.; Griffin, I.; Tucker, C.; Oechsle, O.; Smith, D.; Richardson, P. COVID-19: Combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis., 2020, 20(4), 400-402.
[http://dx.doi.org/10.1016/S1473-3099(20)30132-8] [PMID: 32113509]
[27]
Su, S.; Wong, G.; Shi, W.; Liu, J.; Lai, A.C.K.; Zhou, J.; Liu, W.; Bi, Y.; Gao, G.F. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol., 2016, 24(6), 490-502.
[http://dx.doi.org/10.1016/j.tim.2016.03.003] [PMID: 27012512]
[28]
Tan, D-X.; Hardeland, R. Potential utility of melatonin in deadly infectious diseases related to the overreaction of innate immune response and destructive inflammation: Focus on COVID-19. Melatonin Res., 2020, 3, 120-143.
[http://dx.doi.org/10.32794/mr11250052]
[29]
Vehreschild, J.J.; Moritz, G.; Vehreschild, M.J.G.T.; Arenz, D.; Mahne, M.; Bredenfeld, H.; Chemnitz, J.; Klein, F.; Cremer, B.; Böll, B.; Kaul, I.; Wassmer, G.; Hallek, M.; Scheid, C.; Cornely, O.A. Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: A randomised trial. Int. J. Antimicrob. Agents, 2012, 39(2), 130-134.
[http://dx.doi.org/10.1016/j.ijantimicag.2011.10.009] [PMID: 22169408]
[30]
Wang, J.; Qiao, L.F.; Li, Y.S.; Yang, G.T. Shen Fu injection activate the macrophage NF-kB of rats’ alveolar induced by LPS. Acta Medicinae Universitatis Scientiae et Technologiae Huazhong., 2009, 1, 15-18.
[31]
Wang, L.; Fan, J.; Lin, Y-S.; Guo, Y-S.; Gao, B.; Shi, Q-Y.; Wei, B-Y.; Chen, L.; Yang, L.; Liu, J.; Luo, Z-J. Glucocorticoids induce autophagy in rat bone marrow mesenchymal stem cells. Mol. Med. Rep., 2015, 11(4), 2711-2716.
[http://dx.doi.org/10.3892/mmr.2014.3099] [PMID: 25515523]
[32]
Wang, M.; Cao, R.; Zhang, L.; Yang, X.; Liu, J.; Xu, M.; Shi, Z.; Hu, Z.; Zhong, W.; Xiao, G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 2020, 30(3), 269-271.
[http://dx.doi.org/10.1038/s41422-020-0282-0] [PMID: 32020029]
[33]
Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C-L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020, 367(6483), 1260-1263.
[http://dx.doi.org/10.1126/science.abb2507] [PMID: 32075877]
[34]
Wu, C-N.; Xia, L-Z.; Li, K-H.; Ma, W-H.; Yu, D-N.; Qu, B.; Li, B-X.; Cao, Y. High-flow nasal-oxygenation-assisted fibreoptic tracheal intubation in critically ill patients with COVID-19 pneumonia: A prospective randomised controlled trial. Br. J. Anaesth., 2020, 125(1), e166-e168.
[http://dx.doi.org/10.1016/j.bja.2020.02.020] [PMID: 32200994]
[35]
Wu, D.; Yang, X.O. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect., 2020, 53(3), 368-370.
[http://dx.doi.org/10.1016/j.jmii.2020.03.005] [PMID: 32205092]
[36]
Yang, Y.; Islam, M.S.; Wang, J.; Li, Y.; Chen, X. Traditional Chinese Medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): A review and perspective. Int. J. Biol. Sci., 2020, 16(10), 1708-1717.
[http://dx.doi.org/10.7150/ijbs.45538] [PMID: 32226288]
[37]
Yao, X.; Ye, F.; Zhang, M.; Cui, C.; Huang, B.; Niu, P.; Liu, X.; Zhao, L.; Dong, E.; Song, C.; Zhan, S.; Lu, R.; Li, H.; Tan, W.; Liu, D. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis., 2020, 71(15), 732-739.
[http://dx.doi.org/10.1093/cid/ciaa237] [PMID: 32150618]
[38]
Yue, M.C.; Collins, J.T.; Subramoniapillai, E.; Kennedy, G.A. Successful use of oseltamivir prophylaxis in managing a nosocomial outbreak of influenza A in a hematology and allogeneic stem cell transplant unit. Asia Pac. J. Clin. Oncol., 2017, 13(1), 37-43.
[http://dx.doi.org/10.1111/ajco.12565] [PMID: 27730741]
[39]
Zhang, J.; Ma, X.; Yu, F.; Liu, J.; Zou, F.; Pan, T.; Zhang, H. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv, In press
[40]
Zhang, Y.; Yu, L.; Tang, L.; Zhu, M.; Jin, Y.; Wang, Z.; Li, L. A promising anti-cytokine-storm targeted therapy for COVID-19: The artificial-liver blood-purification system. Engineering (Beijing), in press
[http://dx.doi.org/10.1016/j.eng.2020.03.006] [PMID: 32292628]
[41]
Zhao, J.; Tian, S.S.; Yang, J.; Liu, J.; Zhang, W.D. Investigating the mechanism of Qing-Fei-Pai-Du-Tang for the treatment of novel coronavirus pneumonia by network pharmacology., 2020.
[42]
Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov., 2020, 6, 14-31.
[http://dx.doi.org/10.1038/s41421-020-0153-3] [PMID: 32194980]
[43]
Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; Niu, P.; Zhan, F.; Ma, X.; Wang, D.; Xu, W.; Wu, G.; Gao, G.F.; Tan, W. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020, 382(8), 727-733.
[http://dx.doi.org/10.1056/NEJMoa2001017] [PMID: 31978945]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy